Revelation Biosciences (REVB) Interest & Investment Income (2021)
Revelation Biosciences (REVB) posted quarterly Interest & Investment Income of -$5502.0 for Q4 2021, down 396.92% quarter-over-quarter from $1853.0 in Q3 2021.
Revelation Biosciences (REVB) Interest & Investment Income (2021) Analysis & Trends
Revelation Biosciences (REVB) has reported Interest & Investment Income for 1 consecutive years, with -$5502.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Interest & Investment Income changed N/A year-over-year to -$5502.0; the TTM figure through Dec 2021 stood at $222.0 (changed N/A YoY), while the FY2021 annual figure was $222.0, down 86.04% from the prior year.
- Interest & Investment Income eased to -$5502.0 in Q4 2021 per REVB's latest filing, from $1853.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2038.0 in Q1 2021 and bottomed at -$5502.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -5,502.00 |
| Sep 30, 2021 | 1,853.00 |
| Jun 30, 2021 | 1,833.00 |
| Mar 31, 2021 | 2,038.00 |